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Abstract:  
The primary objective of this study is to analyze the most up-to-date evidence regarding whether 
and how blood sugar regulation impacts cardiovascular health promotion and disease prevention 
by carrying out an umbrella review. Three separate, systematic literature searches identified a 
total of 2,343 articles. Overall, 44 studies were included for data extraction and analysis. The 
included systematic reviews and meta-analyses published between 1 January 2016 and 31 
December 2017 were of good to very good quality (median OQAQ score = 17). Identified 
evidence suggests that cardiovascular prevention services should consider the regulation of blood 
glucose as a key target for intervention. Furthermore, CV prevention should adopt the 
recommendations for effective intervention and service development/training described in this 
review in existing evidence-based practice guidelines. Multidisciplinary teams should be formed 
to deliver multi-component interventions in community-based settings. There may be substantial 
opportunities for integrating CVD prevention and diabetes prevention services. 
 
Condensed Abstract: An umbrella review of up-to-date evidence regarding the role of blood 
sugar regulation in cardiovascular health promotion and disease prevention identified 44 
systematic reviews and meta-analyses. Identified evidence suggests that cardiovascular 
prevention services should consider the regulation of blood glucose as a key target for 
intervention and adopt the recommendations for effective intervention and service 
development/training described in this review. These recommendations extend existing 
evidence-based practice guidelines. There may be substantial opportunities for integrating CVD 
prevention and diabetes prevention services, using multi-disciplinary teams to deliver 
intervention in community settings. 
 
Keywords: blood sugar, cardiovascular health, prevention, umbrella review 
 
Abbreviations 
AMPK Adenosine monophosphate-activated protein kinase 
BCT  Behavior change technique 
BMI  Body mass index 
BP  Blood pressure 
CV  Cardiovascular 
CVD  Cardiovascular diseases 
DBP  Diastolic blood pressure 
DPP-4  Dipeptidyl peptidase-4 
FPG  Fasting plasma glucose 
GLP-1 RA Glucagon-like peptide-1 receptor agonists 
HbA1c Glycated hemoglobin 
HDL-c, High-density lipoprotein cholesterol 
IQR  Interquartile range 
KATP  ATP-sensitive potassium 
LDL-c  Low-density lipoprotein cholesterol 
MI  Myocardial infarction 
PA  Physical activity 
PPG  Postprandial blood glucose 
RCT  Randomized controlled trial 
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SBP  Systolic blood pressure 
SD  Standard deviation 
SGLT2 Sodium-glucose cotransporter 2 
T2DM  Type 2 diabetes mellitus 
TC   Total cholesterol 
TG  Triglycerides  
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Background 
The prevalence of cardiovascular diseases (CVD) is increasing worldwide (1). The 
absolute numbers of deaths caused by CVD has increased by more than 25% between 1990 and 
2010 (2), while decreasing in higher income countries (3). As the number of patients with CVD 
is likely to increase further due to demographic changes, so will the costs of treatment (4). 
Hyperglycemia is a key modifiable risk factor for the development of CVD (5-8), with pre-
diabetes being a major risk factor for the progression to type 2 diabetes (T2DM), which in turn 
increases CVD risk (9). As a part of a multifactorial risk factor intervention, effective reduction 
of hyperglycemia has a positive effect on CVD risk (10). This is true for both high and low 
levels of HbA1c at baseline (11-13). For reasons not well understood so far only non-fatal events 
could be reduced by intensive glucose lowering (14,15). Therefore, it is vital to understand the 
potential prevention and care pathways by which CVD risk is reduced by blood sugar regulation 
to guide prevention of CVD.  
Established mechanisms in cardiovascular health promotion entail developing strategies 
for screening and preventive interventions tackling the mechanisms of disease development (16). 
Although trials of intensive glucose reduction via medication in the past decades showed no 
significant macrovascular benefits (17), recent studies of glucose lowering using glucagon-like 
peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) 
inhibitors have shown sizable reductions in hard CVD endpoints compared to established 
glucose lowering strategies (18,19). This highlights the importance of the mechanisms tackled by 
these drugs in preventing CVD in DM patients. At the same time, lifestyle interventions focusing 
on improving diet, weight loss and physical activity are known to be highly effective in 
preventing progression to type 2 DM (T2DM) in persons with hyperglycemia and increased risk 
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of DM and CVD (20,21). Risk factors for CVD overlap, as high blood pressure, weight, physical 
activity, cholesterol, diet, blood sugar are all interconnected. However, progression to T2DM 
adds considerable risk due to the micro and macrovascular complications of endocrine 
dysregulation (22). Indeed, nearly five decades of research in DM prevention and management 
have largely focused on interventions to identify risk, address behavioral risk factors, and 
improve management of blood sugars, BP, and lipids. There is, therefore, an opportunity for 
preventing CVD risk by focusing on the identification of mechanisms leading to CVD in people 
with hyperglycemia and taking steps to regulate blood glucose.  
However, considerable debate remains in the medical and public health communities 
about whether individual-focused screen-and-treat interventions are a) sufficient and b) the most 
cost-effective approaches (23-26). The benefit from individual-focused interventions is 
potentially life-saving for individuals with high risk or established disease but reaches only a 
small fraction of the population (27). Since T2DM and downstream CVD are both associated 
with wider cultural and societal influences (28), there have been several calls for broader, more 
population-focused interventions that can reach larger groups of people. Some have suggested 
that policy interventions that use regulations, mass media or educational approaches, or 
environmental changes (29-33) will have broader, more cost-effective and sustainable impacts on 
DM and CVD. A whole-population approach aims to minimize the entire distribution of a risk 
factor, even if just by a small degree, to affect the proportion of those at risk (34). 
Evidence-based guidance on individual- or population-based, as well as standardized care 
and prevention pathways are needed to integrate current evidence from trials into guidelines, 
practice and policies (35).  
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Objectives 
The main objective of this study was to carry out an umbrella review (36) of recent 
evidence on interventions – both medical treatments and lifestyle modification – targeting blood 
sugar regulation. This will help to inform efforts to improve cardiovascular health via a more 
detailed consideration of blood glucose regulation pathways. Based on Andersen’s (37) Model of 
Health Services’ Use, the study group combined four perspectives in one overall review. The 
structure of the review covers medical treatments of blood sugar regulation contributing to CVD 
risk, factors influencing individual health behavior, and factors enabling population-based 
interventions. Based on this model, guidance for the development of future health promotion 
programs and competencies for training can be derived.  
As illustrated by Figure 1, the specific objectives are: 
 To outline likely pathophysiological mechanisms by which blood glucose regulation 
affects CVD risk and evidence on pharmacological interventions targeting these 
pathways (1a and 1b) 
 To identify evidence-based individual level interventions for supporting effective 
behavior change to regulate blood sugar and thereby reduce CVD risk (1a and 1b)  
 To identify evidence-based population level interventions for supporting effective 
behavior change to regulate blood sugar and thereby reduce CVD risk (2a and 2b).  
 To translate key findings into applicable recommendations highlighting competencies for 
training for health promotion and for standardizing health promotion care pathways (3a 
and 3b). 
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Methods 
In order to address the above aims, extensive automated and manual searches were 
performed to identify relevant systematic reviews of randomized controlled trials and meta-
analyses. Database reviews were conducted by PT, LH, CG, JL, MMA and HM, duplicates were 
removed, and search results were triaged to the section writing teams (section 1 MMA, HM; 
section 2 CG, JL; section 3 MKA, MBW; section 4 PT, LH). Two reviewers completed 
screening of studies, data extraction, and quality assessments per section. Any discrepancies 
between the reviewers were resolved by discussion. Three core sections meant to answer the 
primary research question: 
In what ways should blood sugar regulation be taken into account by future 
cardiovascular health promotion and prevention programs?  
Search strategy and eligibility criteria 
Comprehensive electronic searches were conducted in Medline and Embase for 
systematic reviews of RCTs or meta-analyses published between 1 January 2016 and 31 
December 2017. The search areas were ‘MeSH terms’ or ‘title, abstract and key words’. To 
identify the main physiopathological mechanisms driving CV outcomes in T2DM patients 
(section 1), the search terms and synonyms covered the following criteria: study designs 
(systematic reviews and meta-analysis of RCTs), interventions (glucose lowering, in 
combination with BP and lipid lowering), mechanisms (physiopathological, pathophysiological), 
and measured outcomes (BP regulation, lipid profile regulation, CV events and mortality). To 
identify intervention components associated with effectiveness for individual level behavior 
change to address blood glucose regulation (section 2), search terms were identified and searches 
were constructed to combine each of the following areas: CVD risk factors, blood sugar 
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regulation, behavioral intervention targets and specific study designs (systematic reviews and 
meta-analysis of RCTs). To investigate population-level interventions (section 3), a search for 
reviews of exposures like mandates, policies, programs, mass education, or built environmental 
changes that may be associated with widespread changes in blood sugar was conducted. 
Systematic reviews and meta-analyses reporting glucose-related outcomes, both actual blood 
glucose (HbA1c, fasting blood glucose) or diabetes related outcomes (prevalence, incidence, or 
rates of acute or chronic complications) were included. Articles identified in any of the previous 
searches focusing on standardized care pathways, especially interventions in the primary care 
setting, were summarized in section 4. 
The study groups hand-searched any systematic reviews and meta-analyses to include 
studies which may have been missed by the automated search. In order to provide a consistent 
picture of the current state of the art, single landmark studies of the past 15 years, as well as 
highlights of expected findings derived from current studies were also included. 
After screening of title and abstracts all sections excluded reviews or meta-analysis which 
did not include humans, did not meet one of the four aims or were published before 1 January 
2016. Although originally intended, a thorough focus on systematic reviews and meta-analyses 
primarily derived from RCTs was not feasible for population-level interventions (section 3) since 
their characteristics hardly allow for testing in an experimental setting. After full-text screening, 
studies were excluded if they did not inform the research question or were below the threshold of 
the OQAQ measurement (see below). 
Quality assessment and standardized reporting 
For quality assessment of the identified reviews, a modified version of Oxman and 
Guyatt’s Overview Quality Assessment Questionnaire (OQAQ) (38) was used. The OQAQ 
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consists of nine quality items, each comprising the dimensions ‘yes’, ‘no’ or ‘partially/can’t tell’, 
carrying scores of 2, 1 and 0, resulting in an overall score of 0 to 18 points. To maximize the 
quality of evidence considered, we rejected studies with an OQAQ score less than 14. 
Standardized reporting was ensured by applying the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) reporting framework (39).  
Data extraction and analysis 
Although carried out independently, the three sections applied identical methods for data 
extraction, analysis and reporting. A revised template for extracting/summarizing empirical 
evidence from a prior systematic review of reviews (40) was applied. Not all included systematic 
reviews and meta-analyses referred to glycemic control as a primary outcome, or distinguished 
between primary, secondary and surrogate outcomes. Therefore a presentation of results 
according to the outcome levels is not provided. Finally, implications for standardizing health 
promotion care pathways and competencies for health care workers were extracted from each of 
the three sections. 
Results 
Section 1 - Pathophysiological pathways of blood glucose regulation on CVD risk 
Review characteristics 
Overall 769 references were identified including 455 from our section-specific search 
string, 305 articles identified by the searches for sections 2 and 3, and 9 references from hand 
searching (Fig. 2). After reviewing the title and abstract, 685 studies were excluded. Details of 
the evidence extracted are provided in Online Table 1. 
Study quality 
11 
On a scale of 0-18, the median OQAQ score of 17 included studies was 17 (IQR = 1.5), 
indicating that they were high quality systematic reviews and meta-analyses. 
Outcomes and mechanisms 
Individuals with T2DM have a 2 to 3-fold greater risk of CVD than people without 
T2DM, with women showing an increased elevated risk compared to men (2.5 fold risk increase 
in women compared to 1.7-fold in men) (41). Moreover, people with T2DM have an increased 
risk of long-term mortality following coronary revascularization in both stable ischemic and 
ACS populations (42-46). Through outlining the recently analyzed glucose lowering 
pharmacological interventions, the pathophysiological mechanisms leading to cardiovascular 
(CV) events in T2DM patients will be presented. 
Intensive glucose lowering in landmark trials such as UKPDS (47), ACCORD (48), 
ADVANCE (27), and VADT (49) mainly utilizing insulin or sulfonylureas had improved 
microvascular but not macrovascular outcomes, suggesting that glucose lowering in itself does 
not reduce CV events. Hence, reduction of hyperglycemia using insulin therapy does not reduce 
the risk of CV events (50). Metformin may lower the incidence of CVD, but this is still not 
proven (51). Moreover, the latest analyses addressing intensive glucose lowering show that in 
comparison to less intensive therapy, intensive glucose lowering had no influence on CV 
mortality, but reduced the risk of myocardial infarction (52) in addition to a reduction in the risk 
of diabetic nephropathy and retinopathy (53). Hence, managing blood glucose alone in T2DM 
does not seem to reduce macrovascular CV events and targeting other mechanisms should be 
explored. 
Using dipeptidylpeptidase 4 (DPP-4) inhibitors for glycemic control through augmenting 
the bioavailability of GLP-1 held the promise of improved CV outcomes from pre-clinical 
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studies but it failed to be proven in clinical trials to date (54). Some DPP-4 inhibitors even 
increase the risk of hospitalization for heart failure (55). Given the broad physiological activity 
and distribution of DPP-4, speculation arose about the off-target effects of DPP-4 inhibitors 
including their impact on sympathetic nervous system leading to cardiotoxicity (56). Although 
GLP-1 RA reduce hyperglycemia through the same pathway as DPP-4 inhibitors, they are 
associated with improved CV outcomes and have less adverse effects. 
Meta-analyses found that GLP-1 RA 1) reduced body weight, systolic BP, triglycerides 
(TG), and low-density lipoprotein cholesterol (LDL-c) better than insulin (57), 2) were 
associated with a lower risk of myocardial infarction after long-term treatment in comparison to 
sulfonylurea-based therapy (18), 3) reduced the risk of all-cause and CV mortality in comparison 
to placebo (58,59), 4) reduced the risk of severe hypoglycemia (58), and 5) did not increase the 
risk of heart failure, stroke, and microvascular complications including diabetic retinopathy (DR) 
and nephropathy (DN) (59). However, one GLP-1 RA, exenatide, was found to increase the risk 
of arrhythmias in T2DM patients (55). The mechanisms through which GLP-1 RA reduce CV 
risk beyond glucose-lowering effects possibly include reduction in body weight, lipids, blood 
pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical 
atherosclerosis (60).  
Similar to GLP-1 RA, SGLT2 inhibition reduces systolic and diastolic BP (61-63) 
besides reducing glucose reabsorption in the kidney, inducing glucosuria and thereby reducing 
blood glucose. Moreover, SGLT2 inhibition reduces all-cause and CV mortality and major CV 
events (19,54,63,64). Controversies arose, however, regarding the risk of stroke, which ranged 
from no effect (54,63,64) to increased risk (19). The most prominent explanation for 
cardioprotection is the diuretic effect of empagliflozin and consequently the reduction in plasma 
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volume (65). Although conventional diuretics and thiazides show moderate or no reduction in 
risk of heart failure, the diuretic action of empagliflozin does not induce reflex activation of the 
sympathetic nervous system and the consequent neurohormonal cardiac dysregulation. 
Moreover, the proximal inhibition of glucose and sodium reabsorption has beneficial 
consequences on renal function as opposed to distal inhibition (66). Other cardioprotective 
mechanisms include regulation of metabolic processes such as increased plasma glucagon (67) 
and ketone (68) concentrations and reduced uric acid serum levels conferring protection against 
increased BP and vascular damage (69). Another theory is derived from data on reduced vascular 
oxidative stress and inflammation after treatment (70), conferring a reduction in aortic stiffness, 
an independent risk factor of CV mortality (71). Hence, the metabolic effects of SGLT2 
inhibitors leading to weight loss, blood pressure reduction, natriuresis, and improved renal 
function reduce major adverse cardiac events, primarily CV death, independent of its glucose 
lowering activity. Whether use of these agents alone eliminates the need for BP and lipid 
lowering therapies needs to be addressed. 
The landmark trials (27,47-49) investigated combining intensive glucose lowering with 
BP and lipid lowering therapies, termed multifactorial interventions. In recent analyses, 
multifactorial interventions reduced CV mortality in addition to improving CV outcomes (72). 
However, intensive BP lowering in (already well-controlled) T2DM patients had more risks than 
benefits. In one analysis, the renin–angiotensin system blockers were most effective in T2DM 
patients in reducing cardiovascular risk vs. placebo, but there was little or no further benefit in 
lowering systolic BP below 130 mm Hg (73). Furthermore, although antihypertensive treatment 
reduced the risk of all-cause mortality, myocardial infarction, and heart failure in T2DM patients 
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with baseline systolic BP between 140-150 mm Hg, the risk of CV mortality increased if the 
baseline systolic BP was lower than 140 mm Hg (74). 
Taken together, the analyses presented above suggest that pharmacological interventions 
improving glycemic control in people with T2DM can lead to improvements in CV outcomes. 
BP regulation seems to be a key pathway mediating this effect. Preventing progression to T2DM 
in those at risk is also a key risk-reduction pathway.  
Strengths and limitations 
The included reviews are of high quality and represent the latest evidence of intervention 
efficacy in relation to CVD risk reduction through blood glucose management in adults with 
T2DM. Although many studies of case-control or observational nature addressed the association 
of genetic polymorphisms with increased risk of CV outcomes in people with T2DM, the 
exclusion of non-RCT studies from our review minimized the comprehensiveness of 
mechanisms and interventions reviewed. 
Section 2 - Individual level interventions for supporting behavior change to regulate blood 
sugar 
Evidence from landmark studies 
Three “landmark” papers were identified in relation to making recommendations on the 
optimal content of individual lifestyle interventions. These were a prior systematic review of 
reviews of diet and physical activity interventions (40), US national standards for diabetes self-
management education and support (75) and public health guidance on diabetes prevention from 
the UK’s National Institute for Health and Clinical Excellence (NICE) (76). Existing 
recommendations from these sources are summarized in Table 1 and are supplemented with the 
main evidence from the current review. 
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Review characteristics 
Intervention characteristics: Our searches identified 861 articles, of which 24 met both 
the selection and quality criteria (77-100) (Figure 2). The characteristics of the included reviews 
are provided in Online Table 2.1. We identified 95 analyses relating intervention components to 
effectiveness (Online Tables 2.2 to 2.9) and 19 effectiveness analyses (Table 2.1). Full details of 
these 114 analyses are presented in Online Table 2.2 and a summary is provided below.  
Study quality 
The methodological quality of included reviews was generally good (median OQAQ 
score = 16; IQR = 3). The most common methodological weakness was the lack of use of study 
quality data to inform analyses (e.g. by excluding low quality trials). 
Outcomes/ Effective components of interventions 
Overall effectiveness: Evidence from seven systematic reviews (78,82,88,90,94,96,100) 
found that individual lifestyle interventions targeting physical activity and/or diet were effective 
in reducing blood glucose (HbA1c, fasting plasma glucose, fasting insulin, HOMA-IR and 2-
hour blood glucose) for up to 54 months, reducing diabetes incidence in people at risk of 
developing type 2 diabetes for up to 72 months and in reducing weight at up to 52 months of 
follow up. However, there was considerable variation in outcomes between studies, indicating 
the importance of understanding what content and delivery factors are associated with increased 
effectiveness. 
Evidence from six systematic reviews focusing on maintenance of effects (78,80-
82,90,100) found a reduction in effects on both blood glucose and weight over time (for up to 60 
months of follow up).  
Components of interventions associated with increased effectiveness 
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Recommendations derived from both the current review and the landmark papers are 
presented in Table 1. 
Strengths and limitations 
The included reviews are of high quality and represent the latest evidence on components 
of interventions related to effectiveness in reducing blood sugar and the related risk factors of 
weight and physical activity. Our consideration of evidence relating to blood glucose regulation 
adds meaningful new recommendations to existing guidance on CV risk prevention (Table 1). 
Relating the findings to prior evidence-based recommendations helps to minimize sampling bias 
due to the time-limits on our search strategy. However, as most interventions targeted multiple 
behaviors, it was impossible to identify components associated with changes in specific 
behaviors. 
Section 3 - Population level interventions for supporting behavior change to regulate blood 
sugar 
Review characteristics 
Based on the electronic database searches, 85 articles were assessed for inclusion. Of 
these, 75 were excluded because the systematic review objectives were unrelated (34), the 
reviews evaluated individual-focused interventions (17), and/or assessed clinical care models 
(10) or competencies of personnel (14) to address diabetes prevention or management. Although 
an additional hand search was carried out, no additional systematic reviews that meeting the 
eligibility criteria were identified.  
In total, 10 full-text articles were reviewed for inclusion. Of these, seven review articles 
were excluded for the following reasons: did not report glucose-related outcomes (n = 3); were 
not reviews of population level interventions (n = 2); or only included one study with both a 
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population level intervention and a glucose outcome (n = 2). The three remaining articles 
included one systematic review (101) and two systematic review/meta-analyses (102,103). 
Study quality 
All included studies were of excellent quality scoring 17 or higher on an 18-point scale.  
Outcomes/ Effective components of interventions 
Each of the included studies did not focus on unique intervention strategies; instead, they 
summarized the results related to population-level efforts targeted at a particular disease-related 
outcome (recognizing early symptoms for type 1 diabetes (101) or a specific community setting 
(worksites (102,103)). Deylami and colleagues (101) summarized the evidence for awareness 
campaigns about early type 1 diabetes symptoms in children targeted to the population and 
primary healthcare professionals. The authors reported that the programs, which included 
educational posters, reusable shopping bags, and/or provision of glucose testing equipment to 
healthcare providers, reduced the rates of diabetic ketoacidosis (rates of diabetic ketoacidosis 
were reduced in 4/7 studies).  
Two reviews (102,103) summarized the data around worksite-based changes and cardio-
metabolic outcomes. Both reviews included studies using a variety of intervention models 
including one or more of the following: individual or group-based education, medical testing, 
electronic messaging, online programs, self-monitoring of weight and/or physical activity, 
physical activity prescriptions, educational materials, active workstations, and provision of 
healthy meals. Reed et al (102) reported on 24 studies (20 were included in the meta-analysis) 
that examined the effectiveness of workplace interventions for improving moderate-to-vigorous 
activity levels and cardio-metabolic outcomes among working adult women in high-income 
country settings. Two of the included studies reported changes in blood glucose; in the meta-
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analysis, these interventions were shown to significantly reduce blood glucose levels among 
participants (-0.18 mmol/L, 95% CI -0.29—0.07). In their meta-analysis, Shrestha and 
colleagues (103) concluded that workplace dietary interventions significantly reduced HbA1c 
and reduced fasting glucose among participants (pooled results from the meta-analysis: -0.18% 
reduction in HbA1c, 95% CI −0.29 to −0.06; -2.60 mg/dL fasting glucose, 95% CI –5.27 to 
0.08).  
Two of the excluded articles included very limited data (1 study in each review) around 
population-based interventions and glycemic outcomes. In their review of interventions to reduce 
ischemic heart disease in sub-Saharan Africa, Ebireri et al (104) included one study that showed 
a mass media education campaign had no effects on fasting blood glucose levels (105). When 
reviewing the associations between medication copays and both medication adherence and health 
outcomes, Gourzoulidis and colleagues (106) found only one study that reported HbA1c 
outcomes after a copay increase [a $5 copay increase was significantly associated with a 0.1 
point increase in HbA1c (107)]. 
Large-scale dissemination and implementation research related to health policies for 
diabetes is still nascent. While randomized controlled trials (RCT) and especially meta-analysis 
of RCTs are considered the strongest research designs to infer causation (108), many 
environmental-, system-, employer-, or even government-level policy interventions are often not 
amenable ethically or physically possible to evaluate using RCTs. However, causal inference can 
be enhanced through the use of rigorous quasi-experimental study designs and sophisticated 
analytical techniques (109,110). Furthermore, many environmental changes (111) as well as 
regulatory, payment, employer, and health system policies and programs may be opportunities 
for natural experiment evaluations; here, the investigator does not control the intervention, but 
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utilizes the opportunity and easily available data sources to assess whether these policies and 
programs had the intended effects (112) as well as any unintended societal consequences. Many 
of the studies assessing the impacts of policies to influence detection, prevention, and 
management of diabetes have tended to utilize quasi-experimental designs (113,114). 
Many existing studies, as well as those included in this review, only include intermediate 
outcomes and not hard health outcomes – for example, a review of food policies seeking to 
reduce adult obesity and diabetes in the US reported that most studies focused on food 
purchasing patterns (54% of included studies) or self-reported food consumption (46%) with 
only 34% including body weight/composition as outcomes (115). Furthermore, studies with 
biomedical outcomes were more likely to be lower quality studies and less likely to show 
positive results (115). 
Strengths and limitations 
There is limited data on the effectiveness of population-based interventions for improving 
glucose outcomes, including both blood glucose levels (HbA1c, fasting blood glucose) or 
diabetes related outcomes (prevalence, incidence, or rates of acute or chronic complications). No 
evidence was found solely for T2DM. Among the studies identified for this review article, only 
three systematic reviews included sufficient data on glycemic outcomes to be included. 
Furthermore, much of the existing evidence for population-based interventions relies on 
observational studies and should be interpreted with caution. 
Section 4 – Competencies and health promotion care pathways 
Analysis of studies relating to competencies and standardized health promotion care pathways 
Review characteristics 
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Across the three searches, 12 systematic reviews and meta-analyses were identified as 
relating to health care worker involvement and task shifting towards health practitioners other 
than doctors while three other studies were found to be concentrating on care models or quality 
improvement. 
Study quality 
The methodological quality of included reviews was generally good (median OQAQ 
score = 16; IQR = 2). The main methodological weaknesses were a lack of quality assessment 
and sensitivity analyses. Additional issues were not reporting the number of included patients in 
analyses, missing power analysis, and poor reporting on handling of dropouts/missing data/ use 
of intention to treat analysis. 
Outcomes/ Effective components of interventions 
The three studies focusing on integrated care using standardized approaches like the 
chronic care model were all concerned with the management of T2DM (116-118). Integrated 
care is defined following Godwin’s health-system based definition, as a “continuum of health 
promotion, disease prevention, diagnosis, treatment, disease-management, rehabilitation and 
palliative care services, coordinated across the different levels […] of care” (119). While the 
chronic care model used in primary care was evaluated as highly effective in reducing mortality 
and HbA1c, standardized European approaches in multifaceted diabetes care showed only small 
improvements in clinical outcomes like HbA1c. However, one review reported higher potential 
for newly diagnosed patients (117). With respect to integrated care in general, improvement was 
not only shown in patient outcomes, but also for process costs and health service utilization rates 
(118). 
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Pharmacist interventions to reduce the burden of CVD and T2DM were especially 
effective when pharmacists performed a clinical decision making process as part of multi-
disciplinary health care team (93). While improvements in clinical outcomes like HbA1c, 
DBP/SBP or cholesterol were only short term (120), the effect size compared well with care 
delivered by primary physicians (93,120,121) and was found in various settings, including 
primary care and hospitals (93). 
Community-based approaches vary in the type of health care professional involved. The 
majority of the reviews (122-126) were concerned with the involvement of community-based 
pharmacists in the management of CVD or T2DM; two focused on community health worker 
involvement (124,127), while one involved community-based nurses (128). Regardless of the 
health practitioners involved, six studies reported improvements in clinical outcomes, such as 
HbA1c, DBP/SBP, glycemic as well as lipid control and all-cause mortality (122,124-128). 
Improvements in medication adherence were shown by three studies (123,125,126). For health-
related outcomes of interventions delivered by community-based pharmacists, such as quality of 
life, adherence to treatment and/or medication and achievement of health goals, the results are 
more heterogeneous. Their effectiveness relies highly on patient-centeredness, i.e. whether they 
take into account their patients’ health beliefs, goals and literacy (125). Community-based health 
workers interventions were reported to be as effective in achieving lifestyle change in obese 
patients as similar interventions in other primary care settings (124,127). They were, however, 
inferior to commercial weight loss programs for generating weight loss (123). Mixed, yet overall 
positive results were found for the effect of community-based pharmacists on health resource 
usage including hospitalization rate, urgent care and emergency department visits (126). 
However, there is limited evidence on the effectiveness of chronic disease management 
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supervised by pharmacists when studying clinical outcomes such as clinical events and all-cause 
mortality (126). 
Two reviews reported pharmacist-led interventions to be cost-effective (123,126). It is 
worth noting that the positive effect of team approaches or at least strong connections between 
physicians and community-based health practitioners were reported as key factors in the success 
of such interventions (124,125). 
One review found significant effects for nurses prescribing glucose regulation medication 
on glycemic outcomes compared with physicians (129), but not when compared with multi-
disciplinary teams. Limited good quality evidence on CV risk factor improvement (120), a low 
number of studies reporting adverse events (127) as well as missing long-term clinical outcomes 
(124) call for more research on evidence-based health promotion care pathways. 
Strengths and limitations 
No individual search string was applied to identify relevant literature for this part of the 
review. Included studies were identified as a part of the search process identifying literature for 
individual and population-level interventions.  
Implications derived from the sections 1 to 4 
Recommendations for service design/delivery and the training of healthcare professionals 
involved in CVD prevention, drawn from the evidence in all four sections above are summarized 
in Table 2.  
Discussion 
This umbrella review summarizes recent high quality systematic reviews and meta-
analyses, including evidence on pathophysiological, individual and population level 
interventions to regulate blood glucose in people at risk of cardiovascular disease. These findings 
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may serve to help stakeholders develop recommendations for blood sugar regulation to reduce 
CV risk (Table 2). 
An overview of the efficacy of interventions on the individual- or population-levels to 
regulate blood sugar is presented, with an emphasis on the need to reduce cardiovascular risk.  
The latest analyses demonstrate that intensive glucose lowering, once thought to have no 
benefit in CV outcomes, can reduce micro- and macrovascular morbidities and CV mortality. 
Multifactorial interventions that combine intensive glucose lowering with BP and lipid lowering 
have also improved outcomes. However, the baseline BP of T2DM patients must be considered 
before initiating therapy as it can counteract the beneficial impact on CV outcomes (73,74). 
Analyses from recent trials of the glucose lowering drug classes GLP-1 RA and SGLT-2 
inhibitors demonstrate improved glycemic control and CV outcomes in comparison to 
established therapies, with the common mechanism between the classes of drugs being BP 
lowering. Similarly, non-pharmaceutical interventions in T2DM patients, including physical 
activity and diet programs, not only efficiently reduce blood glucose but also BP and 
dyslipidemia, albeit with less side effects than pharmacological interventions.  
The majority of the evidence on lifestyle interventions does not go beyond the regulation 
of blood sugar or focusses on relatively short-term effects on CV risk markers. Additionally, 
existing evidence is negatively affected by underpowered studies, borderline significant results 
or other methodological weaknesses (130,131). Consequently, there is a need for evidence on 
hard, longer-term CV outcomes resulting from lifestyle intervention in people with glucose 
dysregulation. The identified evidence on individual level behavioral interventions supported 
existing recommendations on the content and delivery of behavior change interventions for 
diabetes prevention and diabetes management (40,75,76), but also supported the use of behavior 
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change theory in intervention design, the need for high quality delivery of person-centered 
delivery techniques, involvement of dietitians, self-monitoring of blood glucose (for people with 
diabetes) and the use of digital/mobile platforms to enhance intervention effectiveness. However, 
more research is needed to establish a) the cost-effectiveness of more or less intensive lifestyle 
interventions, b) the effectiveness and cost-effectiveness of interventions to improve the 
maintenance of lifestyle changes, and c) the effectiveness and cost-effectiveness of novel 
interventions to promote lifestyle changes (for instance, it would seem that most existing 
interventions focus on rational/planning and problem-solving strategies for supporting behavior 
change, rather than using novel methods to target impulsive, emotional or social pathways to 
change (132-134)). Future interventions should incorporate text messaging, social media 
networking and other digital health technology to encourage empowerment and self-management 
(135). 
While evidence on interventions aiming at individual behavior change is vast (Tables 1 
and 2), population-based approaches employing multiple mechanisms like mandates, policies, 
programs, mass education, or built environmental changes are scarcely tested for their impact on 
glycemic outcomes. For developing and maintaining new routines of healthy behavior the 
workplace setting provides a potentially supportive environment (136). There are on-going 
programs and larger trials of policy, taxation, built environment, and other interventions focused 
on the broader population (101,137,138). Assessments of these programs and trials should 
provide longitudinal data and more definitive data on the impact of these programs on 
cardiometabolic risk factors and diseases. 
Population-based changes can be especially complicated to evaluate because of wider 
(and sometimes unintended) effects – for example, taxation programs might be considered 
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socially regressive because they disproportionately impact lower socioeconomic classes (139). 
Other researchers recommend several possible areas for intervention at the policy and 
environmental level, such as introducing liability for adverse health effects of food and beverage 
products in combination with individual level prevention approaches (140). 
The review identified evidence for the effectiveness of task shifting from medical doctors 
to community health workers and other community-based health practitioners like nurses and 
pharmacists (124,127). This finding may be of tremendous benefit in rural areas and settings 
where a shortage of services and resources requires a shifting of responsibilities, such as 
prescribing following algorithms and protocols (129). Additionally, the potential for community-
based multi-disciplinary teams to increase effectiveness in both individual and community level 
interventions was observed (93). This is in line with current evidence highlighting significant 
improvements of multi-disciplinary interventions in other areas of chronic disease management 
(141,142). Recent findings also indicate emerging evidence to support policy for chronic care 
management in primary care and community settings (143), especially since integrated care has 
proven to be cost-effective (144). 
Strengths and Limitations  
This study used robust, high quality systematic reviewing methods to generate an 
overview of evidence on glucose-regulation. Systematic umbrella reviews are helpful to 
summarize complicated and vast amounts of research to efficiently inform decision makers in the 
health sector, such as policy makers and clinicians (36).  
A focus on this high quality data limits the risk of overlooking major trends on a given 
subject. However, there are some limitations that need to be acknowledged. Some relevant 
research may not have been included in meta-analyses, despite being of high quality. Such 
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selection bias may have arisen from limitations in the search terms and range of databases 
searched. Further selection bias might arise from the choice of relevant primary studies by the 
authors of the reviews and meta-analyses included. As the search for systematic reviews and 
meta-analyses on population-wide interventions has shown, experimental trial designs are less 
commonly applied (and may be less appropriate) in the field of community based intervention, 
either due to ethical concerns or simple economic barriers of feasibility. Hence, including 
observational studies or quasi-experimental designs might have generated additional insights. 
Finally, section four did not apply an individual search strategy but relied on reviews identified 
by the other three sections.  
Conclusion 
Overall, this review has outlined the state-of-the-art in relation to the field of blood 
glucose regulation and suggests that this evidence can be used to extend existing guidance for 
CVD prevention (Table 3). 
CV prevention services should consider the regulation of blood glucose as a key target for 
intervention and adopt the recommendations for effective intervention and service delivery 
described in this review, as well as in existing evidence-based practice guidelines. Addressing 
the individual need of patients is key for CV prevention programs and should take into account 
pathophysiological mechanisms and aspects influencing individual behavior change, both on the 
individual as well as the environmental level. Multidisciplinary teams (including pharmacists, 
nurses, or community-health workers) should be formed to deliver multi-component 
interventions in community-based settings. The potential for future services and policy to 
integrate efforts around diabetes prevention, diabetes management and CVD prevention seems 
highly attractive. 
27 
References 
1. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: 
International Diabetes Federation, 2017. 
2. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes 
of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden 
of disease study 2010. Lancet 2012;380:2095-128. 
3. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Rayner M, Townsend N. 
European Cardiovascular Disease Statistics 2017. In: Network EH, editor. Brussels, 
2017. 
4. Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A 
Global Systematic Review. PharmacoEconomics 2015;33:811-831. 
5. Hong KN, Fuster V, Rosenson RS, Rosendorff C, Bhatt DL. How Low to Go With 
Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. J Am Coll 
Cardiol 2017;70:2171-2185. 
6. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for 
cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 
2004;164:2147-2155. 
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and 
incident cardiovascular events. A metaregression analysis of published data from 20 
studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40. 
8. Ali MK, Bullard KM, Saydah S, Imperatore G, Gregg EW. Cardiovascular and renal 
burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 
1988-2014. Lancet Diabetes Endocrinol 2018;6:392-403. 
9. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of 
cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 
2016;355:i5953. 
10. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial 
intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 
2003;348:383-93. 
11. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and 
microvascular complications of type 2 diabetes (UKPDS 35): prospective observational 
study. BMJ 2000;321:405-12. 
12. Waugh N, Shyangdan D, Taylor-Phillips S, Suri G, Hall B. Screening for type 2 diabetes: 
a short report for the National Screening Committee. Health Technology Assessment 
2013;17:Chapter 4. 
13. The Emerging Risk Factors Collaboration, Angelantonio ED, Gao P et al. Glycated 
Hemoglobin Measurement and Prediction of Cardiovascular Disease. JAMA 
2014;311:1225-1233. 
14. Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on 
cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of 
randomised controlled trials. Lancet 2009;373:1765-72. 
15. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular 
outcomes in type 2 diabetes. Diabetologia 2009;52:2288-2298. 
16. Labarthe DR, Dunbar SB. Global cardiovascular health promotion and disease 
prevention: 2011 and beyond. Circulation 2012;125:2667-76. 
28 
17. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive 
Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008;358:2545-2559. 
18. Chou CY, Chang YT, Yang JL et al. Effect of Long-term Incretin-Based Therapies on 
Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-
analysis. Sci Rep 2017;7:15795. 
19. Wu JH, Foote C, Blomster J et al. Effects of sodium-glucose cotransporter-2 inhibitors on 
cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a 
systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016;4:411-9. 
20. Schwarz PE, Greaves CJ, Lindstrom J, Yates T, Davies MJ. Nonpharmacological 
interventions for the prevention of type 2 diabetes mellitus. Nat Rev Endocrinol 
2012;8:363-373. 
21. Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Primary 
Prevention of Cardiovascular Disease in Diabetes Mellitus. J Am Coll Cardiol 
2017;70:883-893. 
22. Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the 
initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood) 
2016;241:1323-31. 
23. Williamson DF, Narayan KM. Identification of persons with dysglycemia: terminology 
and practical significance. Prim Care Diabetes 2009;3:211-7. 
24. Echouffo-Tcheugui JB, Ali MK, Griffin SJ, Narayan KM. Screening for type 2 diabetes 
and dysglycemia. Epidemiol Rev 2011;33:63-87. 
25. Glumer C, Yuyun M, Griffin S et al. What determines the cost-effectiveness of diabetes 
screening? Diabetologia 2006;49:1536-44. 
26. Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T. Efficacy and 
effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic 
review and meta-analysis of screening tests and interventions. BMJ 2017;356. 
27. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular 
Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008;358:2560-2572. 
28. Colagiuri R, Colagiuri S, Yach D, Pramming S. The answer to diabetes prevention: 
science, surgery, service delivery, or social policy? Am J Public Health 2006;96:1562-9. 
29. Nielsen SJ, Popkin BM. Patterns and trends in food portion sizes, 1977-1998. JAMA 
2003;289:450-3. 
30. Brownell KD, Farley T, Willett WC et al. The public health and economic benefits of 
taxing sugar-sweetened beverages. N Engl J Med 2009;361:1599-605. 
31. Novak NL, Brownell KD. Taxation as prevention and as a treatment for obesity: the case 
of sugar-sweetened beverages. Current pharmaceutical design 2011;17:1218-22. 
32. Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. 
N Engl J Med 2007;357:370-9. 
33. Elbel B, Kersh R, Brescoll VL, Dixon LB. Calorie labeling and food choices: a first look 
at the effects on low-income people in New York City. Health Aff (Millwood) 
2009;28:w1110-21. 
34. Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res 
Ed) 1981;282:1847-1851. 
35. Martin GP, Kocman D, Stephens T, Peden CJ, Pearse RM. Pathways to professionalism? 
Quality improvement, care pathways, and the interplay of standardisation and clinical 
autonomy. Sociol Health Illn 2017;39:1314-1329. 
29 
36. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. 
Summarizing systematic reviews: methodological development, conduct and reporting of 
an umbrella review approach. Int J Evid Based Healthc 2015;13:132-140. 
37. Andersen RM. Revisiting the Behavioral Model and Access to Medical Care: Does it 
Matter? J Health Soc Behav 1995;36:1-10. 
38. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin 
Epidemiol 1991;44:1271-1278. 
39. Moher D, Shamseer L, Clarke M et al. Preferred reporting items for systematic review 
and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. 
40. Greaves CJ, Sheppard KE, Abraham C et al. Systematic review of reviews of intervention 
components associated with increased effectiveness in dietary and physical activity 
interventions. BMC Public Health 2011;11:1-12. 
41. Dong X, Cai R, Sun J et al. Diabetes as a risk factor for acute coronary syndrome in 
women compared with men: a meta-analysis, including 10 856 279 individuals and 106 
703 acute coronary syndrome events. Diabetes Metab Res Rev 2017;33. 
42. Bundhun PK, Bhurtu A, Yuan J. Impact of type 2 diabetes mellitus on the long-term 
mortality in patients who were treated by coronary artery bypass surgery: A systematic 
review and meta-analysis. Medicine 2017;96:e7022. 
43. Chen PC, Chua SK, Hung HF et al. Admission hyperglycemia predicts poorer short- and 
long-term outcomes after primary percutaneous coronary intervention for ST-elevation 
myocardial infarction. J Diabetes Invest 2014;5:80-6. 
44. Malmberg K, Yusuf S, Gerstein HC et al. Impact of diabetes on long-term prognosis in 
patients with unstable angina and non-Q-wave myocardial infarction: results of the 
OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 
2000;102:1014-9. 
45. Franklin K, Goldberg RJ, Spencer F et al. Implications of diabetes in patients with acute 
coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 
2004;164:1457-63. 
46. Straumann E, Kurz DJ, Muntwyler J et al. Admission glucose concentrations 
independently predict early and late mortality in patients with acute myocardial infarction 
treated by primary or rescue percutaneous coronary intervention. Am Heart J 
2005;150:1000-6. 
47. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of 
complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. 
48. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME 
et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 
2008;358:2545-59. 
49. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in 
veterans with type 2 diabetes. N Engl J Med 2009;360:129-39. 
50. Li J, Tong Y, Zhang Y et al. Effects on All-cause Mortality and Cardiovascular 
Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral 
Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials. Clin 
Ther 2016;38:372-386.e6. 
30 
51. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-
analysis of randomised trials among people with type 2 diabetes. Diabetologia 
2017;60:1620-1629. 
52. Fang HJ, Zhou YH, Tian YJ, Du HY, Sun YX, Zhong LY. Effects of intensive glucose 
lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-
analysis of data from 58,160 patients in 13 randomized controlled trials. Int J Cardiol 
2016;218:50-58. 
53. Zoungas S, Arima H, Gerstein HC et al. Effects of intensive glucose control on 
microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual 
participant data from randomised controlled trials. Lancet Diabetes Endocrinol 
2017;5:431-437. 
54. Savarese G, D'Amore C, Federici M et al. Effects of Dipeptidyl Peptidase 4 Inhibitors 
and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in 
patients with type 2 diabetes mellitus: A meta-analysis. Int J Cardiol 2016;220:595-601. 
55. Wang T, Wang F, Zhou J, Tang H, Giovenale S. Adverse effects of incretin-based 
therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized 
trials. Diabetes Metab Res Rev 2016;32:843-857. 
56. Packer M. Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically 
Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials. Circ Res 
2018;122:928-932. 
57. Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical 
effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from 
head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 2017;19:216-227. 
58. Zhang Z, Chen X, Lu P et al. Incretin-based agents in type 2 diabetic patients at 
cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on 
cardiovascular and pancreatic outcomes. Cardiovasc Diabetol 2017;16:31. 
59. Gargiulo P, Savarese G, D'Amore C et al. Efficacy and safety of glucagon-like peptide-1 
agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-
analysis. Nutr Metab Cardiovasc Dis 2017;27:1081-1088. 
60. Rizzo M, Nikolic D, Patti AM et al. GLP-1 receptor agonists and reduction of 
cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta 2018. 
61. Baker WL, Buckley LF, Kelly MS et al. Effects of Sodium-Glucose Cotransporter 2 
Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-
Analysis. J Am Heart Assoc 2017;6. 
62. Johnston R, Uthman O, Cummins E et al. Canagliflozin, dapagliflozin and empagliflozin 
monotherapy for treating type 2 diabetes: systematic review and economic evaluation. 
Health Technol Assess 2017;21:1-218. 
63. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of Sodium-Glucose Cotransport-2 
Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic 
Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. J Am 
Heart Assoc 2017;6. 
64. Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and 
cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. 
Acta Diabetol 2017;54:19-36. 
31 
65. Sha S, Polidori D, Heise T et al. Effect of the sodium glucose co-transporter 2 inhibitor 
canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes 
Metab 2014;16:1087-95. 
66. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-
glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 
2014;129:587-97. 
67. Bonner C, Kerr-Conte J, Gmyr V et al. Inhibition of the glucose transporter SGLT2 with 
dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512-
7. 
68. Ferrannini E, Muscelli E, Frascerra S et al. Metabolic response to sodium-glucose 
cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508. 
69. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 
2008;359:1811-21. 
70. Cherney DZ, Perkins BA, Soleymanlou N et al. The effect of empagliflozin on arterial 
stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes 
mellitus. Cardiovasc Diabetol 2014;13:28. 
71. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-
wave velocity and its relationship to mortality in diabetes and glucose intolerance: an 
integrated index of vascular function? Circulation 2002;106:2085-90. 
72. Seidu S, Achana FA, Gray LJ, Davies MJ, Khunti K. Effects of glucose-lowering and 
multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of 
randomized control trials. Diabet Med 2016;33:280-9. 
73. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on 
outcome incidence in hypertension: 10 - Should blood pressure management differ in 
hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of 
randomized trials. J Hypertens 2017;35:922-944. 
74. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood 
pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. 
BMJ 2016;352:i717. 
75. Beck J, Greenwood DA, Blanton L et al. 2017 National Standards for Diabetes Self-
Management Education and Support. Diabetes Care 2017. 
76. National Institute for Health and Clinical Excellence - NICE. Preventing type 2 diabetes: 
risk identification and interventions for individuals at high risk. NICE public health 
guidance 38. Last updated: September 2017 ed, 2012. 
77. Arambepola C, Ricci-Cabello I, Manikavasagam P, Roberts N, French DP, Farmer A. 
The Impact of Automated Brief Messages Promoting Lifestyle Changes Delivered Via 
Mobile Devices to People with Type 2 Diabetes: A Systematic Literature Review and 
Meta-Analysis of Controlled Trials. J Medl Internet Res 2016;18:e86. 
78. Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T. Efficacy and 
effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic 
review and meta-analysis of screening tests and interventions. BMJ 2017;356:i6538. 
79. Baskerville R, Ricci-Cabello I, Roberts N, Farmer A. Impact of accelerometer and 
pedometer use on physical activity and glycaemic control in people with Type 2 diabetes: 
a systematic review and meta-analysis. Diabet Med 2017;34:612-620. 
32 
80. Beishuizen CR, Stephan BC, van Gool WA et al. Web-Based Interventions Targeting 
Cardiovascular Risk Factors in Middle-Aged and Older People: A Systematic Review 
and Meta-Analysis. J Med Internet Res 2016;18:e55. 
81. Cai X, Qiu SH, Yin H et al. Pedometer intervention and weight loss in overweight and 
obese adults with Type 2 diabetes: a meta-analysis. Diabet Med 2016;33:1035-44. 
82. Cradock KA, G OL, Finucane FM et al. Diet Behavior Change Techniques in Type 2 
Diabetes: A Systematic Review and Meta-analysis. Diabetes Care 2017;40:1800-1810. 
83. Cui M, Wu X, Mao J, Wang X, Nie M. T2DM Self-Management via Smartphone 
Applications: A Systematic Review and Meta-Analysis. PloS One 2016;11:e0166718. 
84. Daly B, Tian CJL, Scragg RKR. Effect of nurse-led randomised control trials on 
cardiovascular risk factors and HbA1c in diabetes patients: A meta-analysis. Diabetes 
Res Clin Pract 2017;131:187-199. 
85. Ekong G, Kavookjian J. Motivational interviewing and outcomes in adults with type 2 
diabetes: A systematic review. Patient Educ Couns 2015;99:944-52. 
86. Fu S, Li L, Deng S, Zan L, Liu Z. Effectiveness of advanced carbohydrate counting in 
type 1 diabetes mellitus: a systematic review and meta-analysis. Sci Rep 2016;6:37067. 
87. Joiner KL, Nam S, Whittemore R. Lifestyle interventions based on the diabetes 
prevention program delivered via eHealth: A systematic review and meta-analysis. Prev 
Med 2017;100:194-207. 
88. Modesti PA, Galanti G, Cala P, Calabrese M. Lifestyle interventions in preventing new 
type 2 diabetes in Asian populations. Intern Emerg Med 2015;11:375-84. 
89. Moller G, Andersen HK, Snorgaard O. A systematic review and meta-analysis of 
nutrition therapy compared with dietary advice in patients with type 2 diabetes. Am J 
Clin Nutr 2017;106:1394-1400. 
90. Mudaliar U, Zabetian A, Goodman M et al. Cardiometabolic Risk Factor Changes 
Observed in Diabetes Prevention Programs in US Settings: A Systematic Review and 
Meta-analysis. PLoS Med 2016;13:e1002095. 
91. Odgers-Jewell K, Ball LE, Kelly JT, Isenring EA, Reidlinger DP, Thomas R. 
Effectiveness of group-based self-management education for individuals with Type 2 
diabetes: a systematic review with meta-analyses and meta-regression. Diabet Med 
2017;34:1027-1039. 
92. Porter J, Huggins CE, Truby H, Collins J. The Effect of Using Mobile Technology-Based 
Methods That Record Food or Nutrient Intake on Diabetes Control and Nutrition 
Outcomes: A Systematic Review. Nutrients 2016;8. 
93. Pousinho S, Morgado M, Falcao A, Alves G. Pharmacist Interventions in the 
Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized 
Controlled Trials. J Manag Care Spec Pharm 2016;22:493-515. 
94. Taylor J, Stubbs B, Hewitt C et al. The Effectiveness of Pharmacological and Non-
Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe 
Mental Illness: A Systematic Review and Meta-Analysis. PloS One 2017;12:e0168549. 
95. Thepwongsa I, Muthukumar R, Kessomboon P. Motivational interviewing by general 
practitioners for Type 2 diabetes patients: a systematic review. Fam Pract 2017;34:376-
383. 
96. Sun Y, You W, Almeida F, Estabrooks P, Davy B. The Effectiveness and Cost of 
Lifestyle Interventions Including Nutrition Education for Diabetes Prevention: A 
Systematic Review and Meta-Analysis. J Acad Nutr Diet 2017;117:404-421.e36. 
33 
97. Wang Y, Xue H, Huang Y, Huang L, Zhang D. A Systematic Review of Application and 
Effectiveness of mHealth Interventions for Obesity and Diabetes Treatment and Self-
Management. Adv Nutr 2017;8:449-462. 
98. Yasmin F, Banu B, Zakir SM, Sauerborn R, Ali L, Souares A. Positive influence of short 
message service and voice call interventions on adherence and health outcomes in case of 
chronic disease care: a systematic review. BMC Med Inform Decis Mak 2016;16:46. 
99. Zhu H, Zhu Y, Leung SW. Is self-monitoring of blood glucose effective in improving 
glycaemic control in type 2 diabetes without insulin treatment: a meta-analysis of 
randomised controlled trials. BMJ Open 2016;6:e010524. 
100. Zhang X, Imperatore G, Thomas W et al. Effect of lifestyle interventions on glucose 
regulation among adults without impaired glucose tolerance or diabetes: A systematic 
review and meta-analysis. Diabetes Res Clin Pract 2016;123:149-164. 
101. Deylami R, Townson J, Mann M, Gregory JW. Systematic review of publicity 
interventions to increase awareness amongst healthcare professionals and the public to 
promote earlier diagnosis of type 1 diabetes in children and young people. Pediatr 
Diabetes 2017. 
102. Reed JL, Prince SA, Elliott CG et al. Impact of Workplace Physical Activity 
Interventions on Physical Activity and Cardiometabolic Health Among Working-Age 
Women: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes 
2017;10. 
103. Shrestha A, Karmacharya BM, Khudyakov P, Weber MB, Spiegelman D. Dietary 
Interventions to Prevent and Manage Diabetes in Worksite Settings: a Meta-Analysis. J 
Occup Health 2017. 
104. Ebireri J, Aderemi AV, Omoregbe N, Adeloye D. Interventions addressing risk factors of 
ischaemic heart disease in sub-Saharan Africa: a systematic review. BMJ Open 
2016;6:e011881. 
105. Grace JM, Wilder CJ, Strydom GI. The effect of a physical and a combined health 
promotion intervention programme on some selected health indicators on South African 
colliery executives. South Afr J Res Sports, Phys Educ Recreation 2009;31:9-18. 
106. Gourzoulidis G, Kourlaba G, Stafylas P, Giamouzis G, Parissis J, Maniadakis N. 
Association between copayment, medication adherence and outcomes in the management 
of patients with diabetes and heart failure. Health Policy 2017;121:363-377. 
107. Hunt J, Rozenfeld Y, Shenolikar R. Effect of patient medication cost share on adherence 
and glycemic control. Manag Care 2009;18:47-53. 
108. Soumerai SB, Starr D, Majumdar SR. How Do You Know Which Health Care 
Effectiveness Research You Can Trust? A Guide to Study Design for the Perplexed. Prev 
Chronic Dis 2015;12:E101. 
109. Soumerai SB, Ceccarelli R, Koppel R. False Dichotomies and Health Policy Research 
Designs: Randomized Trials Are Not Always the Answer. J Gen Intern Med 
2017;32:204-209. 
110. Basu S, Meghani A, Siddiqi A. Evaluating the Health Impact of Large-Scale Public 
Policy Changes: Classical and Novel Approaches. Ann Rev Public Health 2017;38:351-
370. 
111. Humphreys DK, Panter J, Sahlqvist S, Goodman A, Ogilvie D. Changing the 
environment to improve population health: a framework for considering exposure in 
natural experimental studies. J Epidemiol Community Health 2016. 
34 
112. Craig P, Katikireddi SV, Leyland A, Popham F. Natural Experiments: An Overview of 
Methods, Approaches, and Contributions to Public Health Intervention Research. Annu 
Rev Public Health 2017;38:39-56. 
113. Hill JO, Galloway JM, Goley A et al. Scientific Statement: Socioecological Determinants 
of Prediabetes and Type 2 Diabetes. Diabetes Care 2013;36:2430-2439. 
114. Ackermann RT, Kenrik Duru O, Albu JB et al. Evaluating diabetes health policies using 
natural experiments: the natural experiments for translation in diabetes study. Am J Prev 
Med 2015;48:747-54. 
115. Freudenberg N, Franzosa E, Sohler N, Li R, Devlin H, Albu J. The State of Evaluation 
Research on Food Policies to Reduce Obesity and Diabetes Among Adults in the United 
States, 2000-2011. Prev Chronic Dis 2015;12:E182. 
116. Baptista DR, Wiens A, Pontarolo R, Regis L, Reis WC, Correr CJ. The chronic care 
model for type 2 diabetes: a systematic review. Diabetol Metab Syndr 2016;8:7. 
117. Bongaerts BWC, Müssig K, Wens J et al. Effectiveness of chronic care models for the 
management of type 2 diabetes mellitus in Europe: a systematic review and meta-
analysis. BMJ Open 2017;7:1-16. 
118. Busetto L, Luijkx KG, Elissen AMJ, Vrijhoef HJM. Context, mechanisms and outcomes 
of integrated care for diabetes mellitus type 2: a systematic review. BMC Health Serv 
Res 2016;16:18. 
119. Goodwin N. Understanding Integrated Care. Int J Integr Care 2016;16:6. 
120. Babar ZU, Kousar R, Murtaza G, Azhar S, Khan SA, Curley L. Randomized controlled 
trials covering pharmaceutical care and medicines management: A systematic review of 
literature. Res Social Adm Pharm 2018;14:521-539. 
121. Aguiar PM, Brito Gde C, Lima Tde M, Santos AP, Lyra DP, Jr., Storpirtis S. 
Investigating Sources of Heterogeneity in Randomized Controlled Trials of the Effects of 
Pharmacist Interventions on Glycemic Control in Type 2 Diabetic Patients: A Systematic 
Review and Meta-Analysis. PLoS One 2016;11:e0150999. 
122. Asayut N, Sookaneknun P, Chaiyasong S, Saramunee K. Outcomes, costs and 
stakeholders' perspectives associated with the incorporation of community pharmacy 
services into the National Health Insurance System in Thailand: a systematic review. Int J 
Pharm Pract 2018;26:16-27. 
123. Brown TJ, O'Malley C, Blackshaw J et al. Exploring the evidence base for Tier 3 weight 
management interventions for adults: a systematic review. Clin Obes 2017;7:260-272. 
124. Seidu S, Walker NS, Bodicoat DH, Davies MJ, Khunti K. A systematic review of 
interventions targeting primary care or community based professionals on cardio-
metabolic risk factor control in people with diabetes. Diabetes Res Clin Pract 
2016;113:1-13. 
125. Deters MA, Laven A, Castejon A et al. Effective Interventions for Diabetes Patients by 
Community Pharmacists: A Meta-analysis of Pharmaceutical Care Components. Ann 
Pharmacother 2017:1060028017733272. 
126. Greer N, Bolduc J, Geurkink E et al. Pharmacist-led Chronic Disease Management: A 
Systematic Review of Effectiveness and Harms Compared With Usual Care. Ann Intern 
Med 2016. 
127. Jeet G, Thakur JS, Prinja S, Singh M. Community health workers for non-communicable 
diseases prevention and control in developing countries: Evidence and implications. PloS 
one 2017;12:e0180640. 
35 
128. Massimi A, De Vito C, Brufola I et al. Are community-based nurse-led self-management 
support interventions effective in chronic patients? Results of a systematic review and 
meta-analysis. PLoS One 2017;12:e0173617. 
129. Tabesh M, Magliano DJ, Koye DN, Shaw JE. The effect of nurse prescribers on 
glycaemic control in type 2 diabetes: A systematic review and meta-analysis. Int J Nurs 
Stud 2017. 
130. Li G, Zhang P, Wang J et al. The long-term effect of lifestyle interventions to prevent 
diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. 
Lancet 2008;371:1783-9. 
131. The Look Ahead Research Group. Long Term Effects of a Lifestyle Intervention on 
Weight and Cardiovascular Risk Factors in Individuals with Type 2 Diabetes: Four Year 
Results of the Look AHEAD Trial.Arch Intern Med 2010;170:1566-1575. 
132. van Beurden SB, Greaves CJ, Smith J, Abraham C. Techniques for Modifying Impulsive 
Processes Associated with Unhealthy Eating: A Systematic Review. Health Psychol 
2016;35:793-806. 
133. Kim DA, Hwong AR, Stafford D et al. Social network targeting to maximise population 
behaviour change: a cluster randomised controlled trial. Lancet 2015;386:145-153. 
134. Strack F, Deutsch R. Reflective and Impulsive Determinants of Social Behavior. Pers Soc 
Psychol Rev 2004;8:220-247. 
135. Alicia A-M, Josep MS-S, Gemma M-M, Medina FX, Ramon C-C, Francesc S-R. Use of 
mobile phones as a tool for weight loss: a systematic review. J Telemed Telecare 
2014;20:339-349. 
136. Hafez D, Fedewa A, Moran M, O’Brien M, Ackermann R, Kullgren JT. Workplace 
Interventions to Prevent Type 2 Diabetes Mellitus: a Narrative Review. Curr Diab Rep 
2017;17:9-9. 
137. Malambo P, Kengne AP, De Villiers A, Lambert EV, Puoane T. Built Environment, 
Selected Risk Factors and Major Cardiovascular Disease Outcomes: A Systematic 
Review. PloS One 2016;11:e0166846. 
138. Pomeranz JL, Wilde P, Huang Y, Micha R, Mozaffarian D. Legal and Administrative 
Feasibility of a Federal Junk Food and Sugar-Sweetened Beverage Tax to Improve Diet. 
Am J Public Health 2018;108:203-209. 
139. Wright A, Smith KE, Hellowell M. Policy lessons from health taxes: a systematic review 
of empirical studies. BMC Public Health 2017;17:583. 
140. Schwarz PE, Riemenschneider H. Slowing Down the Progression of Type 2 Diabetes: 
We Need Fair, Innovative, and Disruptive Action on Environmental and Policy Levels! 
Diabetes Care 2016;39 Suppl 2:S121-6. 
141. Minneboo M, Lachman S, Snaterse M et al. Community-Based Lifestyle Intervention in 
Patients With Coronary Artery Disease. The RESPONSE-2 Trial. J Am Coll Cardiol 
2017;70:318-327. 
142. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and 
Treatment of Acute and Chronic Heart Failure 2012 of the European Society of 
Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the 
ESC. Eur Heart J 2012;33:1787-847. 
36 
143. Smith SM, Wallace E, O'Dowd T, Fortin M. Interventions for improving outcomes in 
patients with multimorbidity in primary care and community settings. Cochrane Database 
Syst Rev 2016;3:Cd006560. 
144. Cronin J, Murphy A, Savage E. Can chronic disease be managed through integrated care 
cost-effectively? Evidence from a systematic review. Ir J Med Sci 2017;186:827-834. 
145. Michie S, Richardson M, Johnston M et al. The Behavior Change Technique Taxonomy 
(v1) of 93 Hierarchically Clustered Techniques: Building an International Consensus for 
the Reporting of Behavior Change Interventions. Ann Behav Med 2013;46:81-95. 
146. Dunkley AJ, Bodicoat DH, Greaves CJ et al. Diabetes Prevention in the Real World: 
Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes 
and of the Impact of Adherence to Guideline Recommendations: A Systematic Review 
and Meta-analysis. Diabetes Care 2014;37:922-933. 
 
37 
Figure Legends 
Figure 1: Logic order and interdependencies of review sections. Boxes represent the 
objectives of the individual review sections; arrows show the interdependencies of the review 
objectives and their contribution to the explanation of CVD (cardiovascular disease) risk.  
Figure 2: PRISMA Flow Chart of study selection process. PRISMA Flow Chart shows the 
study selection process covering the single steps of identification via two-step-screening (title 
and abstract as well as full text base) for eligibility and inclusion into qualitative synthesis of this 
review. 
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Table 1: Evidence-based recommendations on content for interventions to manage blood 
glucose and cardiovascular risk via changes in diet and physical activity. 
 
Existing Recommendation (from prior 
landmark studies /guidelines) 
New evidence /updates 
To maximize weight loss, interventions 
should promote changes in both diet and 
physical activity (40,76). 
Evidence from the current review supports the 
extension of this recommendation to maximizing 
blood glucose reduction (85,91). The addition of 
physical activity to diet may have less effect on FPG 
or HOMA-IR (100) however.  
Interventions should use established, 
well defined behavior change techniques 
(e.g. Motivational interviewing, action-
planning, relapse prevention) (40,76). 
NB: Such intervention strategies are 
defined in recent taxonomies of behavior 
change techniques (145). 
Evidence from the current review supports the 
extension of this recommendation as follows: 
The use of behavior change theory in designing 
interventions may help to increase effectiveness for 
reducing HbA1c (82,91). However, further evidence is 
needed on which specific theoretical elements are 
essential /optimal. 
Providing people with meals to ensure a balanced diet 
is effective for reducing HbA1c for up to 24 months 
(82). This strategy may be particularly suited for 
people with low problem-solving capabilities. More 
research is needed on cost-effectiveness and 
sustainability.  
Recent evidence on motivational interviewing for 
blood glucose reduction is mixed and this may reflect a 
need for high quality delivery /provider skills to ensure 
success (85,95).  
Including problem-solving and social comparison 
techniques were associated with increased 
effectiveness (82), as was the use of self-regulation 
techniques (see following row). 
Interventions should encourage the use 
of “self-regulation” techniques, which 
are associated with increased 
effectiveness. Self-regulation includes 
specific and individualised goal setting; 
prompting self-monitoring; providing 
feedback on performance and review of 
behavioral goals (40,76). 
Evidence from the current review supports the 
extension of this recommendation:- As well as self-
monitoring of weight or physical activity, self-
monitoring of blood glucose, may be useful for some 
people with T2DM to help regulate blood glucose 
(99). Due regard is needed to ensure ‘meaningful 
monitoring’ and avoiding possible anxiety or 
frustration in individual cases.  
Intervention content and delivery should 
be tailored to individual needs, culture 
and capabilities (e.g. problem-solving 
The current review identified no new evidence on this 
issue. 
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skills, literacy) (75,76). 
Interventions should encourage 
participants to engage social support for 
behavior changes (i.e. engage others who 
are important such as family, friends, and 
colleagues) (40,76). 
The current review identified no new evidence on this 
issue. However, evidence on the benefits of problem 
solving (above) and expert opinion suggests that it 
may be important to address negative social influences 
as well as engaging positive social support. 
Interventions may be delivered by a wide 
range of people /professions, subject to 
appropriate training. This may include 
doctors, nurses, dieticians/nutritionists, 
exercise specialists and lay people, often 
working within a multi-disciplinary team 
(40). 
At least one of the team members 
responsible for facilitating diabetes self-
management services should be a 
suitably trained registered nurse, 
registered dietitian nutritionist, 
pharmacist or certified diabetes educator 
(75). 
Evidence from the current review was broadly 
consistent with the existing recommendation and also 
provided examples of effective glucose-reduction in 
interventions led by health professionals working 
alongside peer supporters and pharmacists (84,91,93). 
Including a dietitian in the provider team is 
specifically recommended for increasing effects on 
glucose and weight in interventions with a dietary 
component (82,89,96). 
Interventions led by peers were less effective for 
reducing blood sugar than those led by health 
professionals (91). 
Interventions may be delivered in a wide 
range of settings, including healthcare 
settings, the workplace, the home, and in 
the community 
The current update did not identify evidence on this 
issue 
Interventions may be delivered using 
group, individual or mixed modes 
(individual and group).  
Evidence from the current review is consistent with 
this recommendation. 
Interventions should include a strong 
focus on maintenance. It is not clear how 
best to achieve behavior maintenance but 
techniques designed to address 
maintenance include: self-monitoring of 
progress, providing feedback, reviewing 
of goals, engaging social support, use of 
relapse management techniques and 
providing follow-up prompts. 
The findings of this review were consistent with this 
recommendation (see above section on overall 
effectiveness) 
 
Interventions should maximize the 
frequency or number of contacts with 
participants (40,76). 
The intensity of intervention should be 
Evidence from the current review is consistent with the 
existing recommendations. For instance, interventions 
lasting 36-72 months reduced diabetes incidence and 
the Number Needed to Treat more than those lasting 6-
24 months (78).  
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matched to the level of risk for 
progression to (or of) T2DM (76).  
Intervention programs should adopt a 
person-centered, empathy-building 
approach (75,76). 
Evidence from the current review is consistent with 
this, although a need for high quality delivery was 
identified (see evidence on motivational interviewing 
above). 
Offer follow-up sessions /support 
/reviews of progress at regular intervals 
following the initial intervention period 
to reinforce positive behavior change and 
provide support, in case of relapse 
(75,76). 
Evidence from the current review was consistent with 
this recommendation. For example, contacting 
participants for the remainder of the follow-up period 
to promote continued adherence to healthy lifestyle 
principles was associated with increased maintenance 
of effects on weight and FPG (81). 
Incorporating text messaging into 
diabetes self-management interventions 
improves engagement and outcomes. 
Along with other digital health 
technologies, it may be possible to 
establish a self-management feedback 
loop with four key elements to provide 
ongoing, real-time engagement in self-
management (75): 
1. Two-way communication 
2. Analysis of patient-generated health 
data 
3. Customized education 
4. Individualized feedback. 
The current review supports and extends this 
recommendation. Web based interventions, text 
messaging and mobile phone apps all had significant 
effects in reducing HbA1c at 3 to 12 months of follow 
up (77,80,83,92,97,98). Digital interventions were also 
effective for increasing physical activity (80,83) and 
reducing weight (80,83,87,97) in the short term (8-12 
months).  
Further evidence, although mixed, suggests that the 
addition of in-person support increases effectiveness 
for weight loss (80,87,90). Hence, the use of „blended“ 
interventions (where patients collect and share data on 
target behaviors /health outcomes with intervention 
providers /health professionals to facilitate a tailored 
discussion) is recommended to support lifestyle 
behavior change. 
  
Left column indicates existing existing recommendations based on prior landmark studies  and 
guidelines); right column shows what the current review adds;  
FPG = Fasting plasma glucose; HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; 
T2DM = Type 2 diabetes mellitus; HbA1c = Glycated hemoglobin 
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Table 2: Summary of practical recommendations for service design /delivery and the 
training of healthcare professionals involved in CVD prevention 
 
Intervention level Practical recommendations 
Pathophysiological 1 Consider baseline BP before initiating intensive BP lowering 
in combination with intensive glucose lowering. 
2 Consider the established patient CVD risk before deciding on 
pharmacological intervention. 
Individual-level 1 Health promotion pathways should include lifestyle 
interventions targeting changes in diet, physical activity and 
weight loss (for those who are overweight or obese) for 
people with diabetes or non-diabetic hyperglycemia (pre-
diabetes), as well as medication-adherence for those with 
diabetes. The intensity of interventions should be matched to 
the level of cardiovascular risk and the risk of T2DM (or its 
complications). 
2 Maximizing effectiveness of individual level interventions 
requires the commissioning of both interventions with 
evidence-based content (see Table 1) and the use of staff with 
the right competencies and training to affect high quality 
delivery. 
3 It is worth considering the development of "blended" 
interventions, where mobile /internet based technologies are 
used to share information between the patient and the 
clinician. This can facilitate helpful dialogue and help to 
facilitate a therapeutic self-management feedback loop 
including self-monitoring, feedback and individually-tailored 
problem-solving. eHealth interventions may be effective as 
stand-alone interventions for some people (those who have 
the capacity to be pro-active, but should not be relied upon as 
a whole-population solution. 
4 Although temporary changes in weight /lifestyle can have 
beneficial longer term effects on blood glucose (particularly 
in the context of diabetes prevention), greater efforts are 
required to address the (ongoing) problem of relapse 
/reversion to prior habits. This may involve the provision of 
ongoing, regular maintenance contacts beyond the initial 
intervention period. 
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Population-level 1 The workplace setting is a highly attractive environment for 
population-level interventions as it incorporates social 
support in a stable environment. 
2 There is a strong need for programs and trials providing 
longitudinal and more definitive data on the impact of 
population-level interventions on cardiometabolic risk factors 
and diseases. 
General 
recommendations on 
competencies for 
training and 
standardizing health 
promotion care 
pathways 
1 Integration of existing CVD prevention and diabetes 
prevention, or diabetes self-management programs has the 
potential to improve care pathways. 
2 Task-shifting in multidisciplinary care teams, especially 
involving community pharmacist and/or nurses, may improve 
clinical outcomes and may be of special benefit in regions 
where shortage of service limits availability of care. 
3 CVD prevention service provider staff need to have /be 
trained to have the following competencies: 
Delivery of group or individual level behavior change 
interventions including: Facilitation of key behavior change 
techniques, including motivation-building using person-
centered counselling techniques, making action plans, 
supporting self-monitoring (including the use of digital and 
blended care approaches), facilitating barrier identification 
and problem-solving and identifying and addressing social 
influences. 
4 CVD prevention service managers need to have /be trained 
to have the following competencies: 
Understanding the evidence (as presented here) and being 
competent in commissioning /co-design of effective, 
evidence-based behavior change programs and training 
courses that will deliver the above competencies. 
Making the case to policy makers to acquire sufficient 
funding to deliver effective lifestyle interventions. Cutting 
corners when translating clinical intervention programs into 
real-world settings is likely to undermine effectiveness and 
cost-effectiveness (146). 
Designing stepped care pathways to ensure that the type / 
intensity of intervention is mapped to individual needs and 
capabilities. 
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Left column shows the focus of the individual review sections (pathophysiological and lifestyle 
interventions targeting the individual and the population); right column shows practical recommendations 
derived from the evidence identified in each section; last row synthesizes the evidence into general 
recommendations on competencies for training and standardizing health promotion care pathways for the 
individual sections;  
BP = Blood pressure; CVD = Cardiovascular disease; T2DM = Type 2 diabetes mellitus; eHealth = 
electronic health 
